Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Completed · Phase 2 · Has a placebo group
Conditions studied: Plaque Psoriasis
In brief
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of 12 weeks of treatment with Apo805K1 in subjects with moderate to severe chronic plaque psoriasis.
Key facts
- Study ID
- NCT01483924
- Run by
- ApoPharma
- People needed
- 60
- Starts
- 2011-11-01
- Expected to finish
- 2013-10-01
- Last updated by the study team
- 2015-02-20
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Axis Clinical Trials — Los Angeles, California, United States
- Axis Clinical Trials — Los Angeles, California, United States
- Menter Dermatology Research Institute — Dallas, Texas, United States
- Center for Clinical Studies — Houston, Texas, United States
- Center for Clinical Studies — Houston, Texas, United States
- The University of Utah — Salt Lake City, Utah, United States
- Innovaderm Research Inc. — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.